EA202192631A1 - ANTI-CANCER COMPOUNDS TARGETING NUCLEAR HORMONAL RECEPTORS - Google Patents

ANTI-CANCER COMPOUNDS TARGETING NUCLEAR HORMONAL RECEPTORS

Info

Publication number
EA202192631A1
EA202192631A1 EA202192631A EA202192631A EA202192631A1 EA 202192631 A1 EA202192631 A1 EA 202192631A1 EA 202192631 A EA202192631 A EA 202192631A EA 202192631 A EA202192631 A EA 202192631A EA 202192631 A1 EA202192631 A1 EA 202192631A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds targeting
cancer compounds
hormonal receptors
targeting nuclear
nuclear hormonal
Prior art date
Application number
EA202192631A
Other languages
Russian (ru)
Inventor
Дэвид Ханг
Сон Мин Фам
Сарваджит Чакраварти
Цзиюнь Чэнь
Джаякант Канканала
Джереми Д. Петтигрю
Ануп Барде
Анджан Кумар Наяк
Original Assignee
Нувейшн Био Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Нувейшн Био Инк. filed Critical Нувейшн Био Инк.
Priority claimed from PCT/US2020/032672 external-priority patent/WO2020232119A1/en
Publication of EA202192631A1 publication Critical patent/EA202192631A1/en

Links

Landscapes

  • Steroid Compounds (AREA)

Abstract

Данное описание относится к противораковым соединениям, полученным из связывающих ядерный стероидный рецептор соединений, к содержащим их продуктам, а также к способам их применения и получения.This disclosure relates to anticancer compounds derived from nuclear steroid receptor binding compounds, products containing them, and methods for their use and preparation.

EA202192631A 2019-11-20 2020-05-13 ANTI-CANCER COMPOUNDS TARGETING NUCLEAR HORMONAL RECEPTORS EA202192631A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962938218P 2019-11-20 2019-11-20
PCT/US2020/032672 WO2020232119A1 (en) 2019-05-14 2020-05-13 Anti-cancer nuclear hormone receptor-targeting compounds

Publications (1)

Publication Number Publication Date
EA202192631A1 true EA202192631A1 (en) 2022-03-22

Family

ID=81077476

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202192631A EA202192631A1 (en) 2019-11-20 2020-05-13 ANTI-CANCER COMPOUNDS TARGETING NUCLEAR HORMONAL RECEPTORS

Country Status (1)

Country Link
EA (1) EA202192631A1 (en)

Similar Documents

Publication Publication Date Title
EA202092436A1 (en) ANTICANCER COMPOUNDS TARGETING NUCLEAR HORMONAL RECEPTORS
MY198034A (en) Tumor-targeted agonistic cd28 antigen binding molecules
MX2023006482A (en) Bispecific antibodies specific for a costimulatory tnf receptor.
CL2021002986A1 (en) Anticancer compounds targeting nuclear hormone receptors
EA202191107A1 (en) NY-ESO-1 T-CELL RECEPTORS AND METHODS OF THEIR APPLICATION
EA201270815A1 (en) ESTROGEN RECEPTOR MODULATORS AND THEIR APPLICATION
MX2016012830A (en) Bispecific her2 antibodies.
BR112017023849A2 (en) anti-ox40 antibodies and methods of use
EA201491973A1 (en) NEW CONNECTIONS
EA202190485A1 (en) CONNECTIONS MODULATING FXR (NR1H4)
MX2021012205A (en) Heavy chain antibodies binding to psma.
EA201590590A1 (en) ANDROGEN RECEPTOR MODULATORS AND THEIR APPLICATION
CO2018003452A2 (en) Bispecific antibodies against human cd20 and human transferrin receptor and methods of use
EA201370066A1 (en) MODULATORS OF ESTROGEN RECEPTORS AND THEIR APPLICATION
EA201792515A1 (en) SUBSTITUTED COMPOUNDS OF TETRAHYDROCHINOLINONE AS MODULATORS OF RHTINOID ORPHANE GAMMA RECEPTORS (RORγ)
EA201792520A2 (en) METHODS AND COMPOSITIONS FOR DETERMINATION OF RESISTANCE TO THERAPY, AIMED AT AN ANDROGENIC RECEPTOR
AR093788A1 (en) IMMUNOTHERAPY WITH LINK AGENTS
EA201592214A1 (en) ESTROGEN RECEPTOR MODULATOR AND ITS APPLICATIONS
EA201391509A1 (en) SOLID PHASE FORMS OF CABAZITAXEL AND METHODS OF THEIR RECEIVING
UY36302A (en) ANTIGENS, BI-SPECIFIC UNION PROTEIN OF THE ANTI-CGRP RECEIVER / PAC1 RECEIVER AND USES OF THE SAME
BR112018075636A2 (en) anti-egfr drug antibody conjugates
BR112018004246A2 (en) combination comprising immunostimulatory oligonucleotides
TR201909663T4 (en) 2,5-dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor-like-1 (fprl-1) receptor modulators.
MX2018015280A (en) Anti-egfr antibody drug conjugates.
MX2016009877A (en) Novel anti-baff antibodies.